Item request has been placed!
×
Item request cannot be made.
×
Processing Request
X4 Pharmaceuticals Submits NDA of Mavorixafor for Rare Immunodeficiency Disease.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
The article focuses on X4 Pharmaceuticals' submission of a new drug application (NDA) to the FDA for mavorixafor, a potential treatment for WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, an ultra-rare immunodeficiency disease. It mentions WHIM syndrome is characterized by recurrent lung infections, papillomavirus-related warts, and an increased cancer risk, and mavorixafor.
No Comments.